12:29 PM EDT, 10/24/2025 (MT Newswires) -- PMV Pharmaceuticals ( PMVP ) said Friday that updated data from the pivotal portion of an ongoing phase 2 cancer study showed that its rezatapopt investigational therapy achieved confirmed responses in eight advanced tumor types, with the highest overall response at 46% in ovarian cancer.

The company said there was also one confirmed complete response, 18 confirmed partial responses, and three unconfirmed partial responses in the ovarian cancer group. Median duration of response was 8 months, PMV added.

Across all cohorts, the investigational drug achieved a 34% overall response rate, with a median duration of response at 7.6 months, according to a statement. Other advanced solid tumor types included in the study were lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma, all harboring a TP53 Y220C mutation, PMV said.

The company said it targets to submit a new drug application for rezatapopt to potentially treat platinum-resistant or refractory ovarian cancer in Q1 of 2027.

Shares of PMV were up more than 2% in recent trading Friday.

Price: 1.63, Change: +0.04, Percent Change: +2.85